(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-4,5-Dihydroxy-2-[(3R,4S,5R)-2,4,5-trihydroxyoxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:155362

Synonyms

beta-D-gluco-hexopyranosyl-(1->2)-beta-D-xylo-pentopyranosyl-(1->2)-D-xylo-pentopyranose
Glc(b1-2)Xyl(b1-2)Xyl
WURCS=2.0/3,3,2/[a212h-1x_1-5][a212h-1b_1-5][a2122h-1b_1-5]/1-2-3/a2-b1_b2-c1

Definition

References

GlyGen:G95390AP
GlyTouCan:G95390AP

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-4,5-Dihydroxy-2-[(3R,4S,5R)-2,4,5-trihydroxyoxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-4,5-Dihydroxy-2-[(3R,4S,5R)-2,4,5-trihydroxyoxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-4,5-Dihydroxy-2-[(3R,4S,5R)-2,4,5-trihydroxyoxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-4,5-Dihydroxy-2-[(3R,4S,5R)-2,4,5-trihydroxyoxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model